United Therapeutics (UTHR) Expected to Announce Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, July 30th. Analysts expect United Therapeutics to post earnings of $6.89 per share and revenue of $802.13 million for the quarter.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.17 EPS. On average, analysts expect United Therapeutics to post $24 EPS for the current fiscal year and $27 EPS for the next fiscal year.

United Therapeutics Trading Down 0.6%

Shares of NASDAQ UTHR traded down $1.91 during trading hours on Friday, hitting $304.50. 310,921 shares of the company traded hands, compared to its average volume of 372,488. The stock has a market capitalization of $13.74 billion, a price-to-earnings ratio of 12.15, a price-to-earnings-growth ratio of 6.68 and a beta of 0.53. The company's 50 day moving average price is $300.01 and its 200 day moving average price is $316.20. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $417.82.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the completion of the sale, the executive vice president directly owned 36,781 shares in the company, valued at $11,185,469.91. This represents a 23.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. This trade represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,681 shares of company stock valued at $24,628,589 over the last 90 days. 10.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

An institutional investor recently raised its position in United Therapeutics stock. Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 141.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145 shares of the biotechnology company's stock after buying an additional 85 shares during the period. Geneos Wealth Management Inc.'s holdings in United Therapeutics were worth $45,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. UBS Group cut their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research report on Monday, June 30th. Cantor Fitzgerald assumed coverage on United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price on the stock. JPMorgan Chase & Co. cut their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $383.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.